Clinical practice recommendations for the treatment of Alport syndrome: A statement of the Alport Syndrome Research Collaborative

Clifford E. Kashtan, Jie Ding, Martin Gregory, Oliver Gross, Laurence Heidet, Bertrand Knebelmann, Michelle Rheault, Christoph Licht

Research output: Contribution to journalReview articlepeer-review

120 Scopus citations

Abstract

We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin-angiotensin-aldosterone system.

Original languageEnglish (US)
Pages (from-to)5-11
Number of pages7
JournalPediatric Nephrology
Volume28
Issue number1
DOIs
StatePublished - Jan 2013

Bibliographical note

Funding Information:
The Alport Syndrome Treatments and Outcomes Registry (C.K., M.G., M.R., C.L.) receives support from private donors and the Alport Syndrome Foundation ( www.alportsyndrome.org ). The European Alport Registry is supported by the Association pour l’Information et la Recherche sur les Maladies Rénales Génétiques (AIRG) (to O.G.) and the KfH Foundation Preventive Medicine (Fritz-Scheler Stipendium of the German Society of Nephrology) (to O.G.). The EARLY PRO-TECT Alport trial is funded by the German Ministry of Education and Research (O.G.).

Keywords

  • Aldosterone inhibitor
  • Alport syndrome
  • Angiotensin receptor blocker
  • Angiotensin-converting enzyme inhibitor
  • Proteinuria

Fingerprint

Dive into the research topics of 'Clinical practice recommendations for the treatment of Alport syndrome: A statement of the Alport Syndrome Research Collaborative'. Together they form a unique fingerprint.

Cite this